How do we improve MTX adherence? Biochemical measure of MTX adherence 37% of patients starting a biologic do not take their MTX (!) Those who do respond better to first Biologic at 6 Mo than those who don’t 37% biologic responders = non adherent POS0313 #EULAR23 @Rheumnow https://t.co/L1Mkqpg1Aj

#EULAR2023 #LB0001 Data from Phase 2 RCT in China showed novel therapy, TLL-018, dual JAK1/Tyk2-i showed superior response to Tofacitinib. Safety profile were similar. Interesting to see data in Phase 3. May be an option for difficult to treat Rheumatoid Arthritis @RheumNow https://t.co/Db5QhzNUC1

#EULAR2023 Before the Highlights sessions, do come along to a session on Novel Mechanism of Cell Death at 12 noon Space 3. We have great line up of speakers 👍🏽🙌🏻 https://t.co/ObcC11uxz0

What about a new oral drug in active #rheumatoid #arthritis vs #JAKi #Tofacitinib? TLL-018 a potent JAK1/TYK2 inhibitor was compared with #Tofa and dose ranging of 10, 20, 30 mg of TLL-018 and many Pts w past TNFi and w JAKi. High dose won #EULAR2023 @RheumNow @eular_org LB0001 https://t.co/UXhT7LV1oD

DISSOLVE 1&2 SEL 212 = tolerogenic nanoparticles containing rapamycin (SEL-110) + pegadricase (SEL-037) Meets primary endpoint in 2 RCTs High dose response 56% & 46% 97% reduction in sUA Infusion reaction 4%, stomatitis 8% Anaphylaxis 4 cases @RheumNow #EULAR23 LB0002 https://t.co/21HieM7NfC

#EULAR23 – Day 1 Report The opening Plenary session and presidential address was followed by a number of overview and review sessions with but a half-day of abstracts presentations, on several therapeutic areas including JIA, COVID and more. https://t.co/7TayWx8SR6 https://t.co/p1K1MduPmO

Promising new therapies in SLE Dr. Yuz Yusof ( @Yuz6Yusof ) weighs in. The pharmacology treatment in SLE is a rapidly expanding field of research that provides excitement and optimism to both the patients and the clinicians. https://t.co/0G6EMYp2mb https://t.co/Yc31sR4fRE

An update on JAK inhibitors and cardiovascular risks Dr. Antoni Chan ( @synovialjoints ) shares #EULAR23 developments on JAK/TYK2 inhibitors. https://t.co/yZqHEg73bn https://t.co/CzVH62LEgL

The key data for treating clinically suspect arthralgias (CSA): TREAT-EARLIER (MTX) ARIAA, APIPPRA (abatacept) but what we need to do going forward: stratify pts better for studies predict individual risk better, to weight up risk-benefit of intervention #EULAR2023 @RheumNow https://t.co/h3gNIyLxPY

Key arguments for CSA skeptics: - definitions, imaging aren’t anywhere near as good as our own suspicion as clinicians is - we still struggle to prevent RA - it’s easy to go down a therapeutic slippery slope, and hard to track back - labels are hard to remove #EULAR2023 @RheumNow https://t.co/4adop3IR8g